What Technical Indicators Show About Baudax Bio Inc. (BXRX)?

0
78

Baudax Bio Inc. (NASDAQ:BXRX) traded with an addition of $1.36 to close at $3.66 on Thursday, an upside of 59.13 percent. An average of 5,522,533 shares of common stock have been traded in the last five days. There was a gain of $1.39 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 3,245,473 shares traded, while the 50-day average volume stands at 1,312,356.

BXRX stock has decreased by -53.29% in the last month. The company shares reached their 1-month lowest point of $1.55 on 12/19/22. With the stock rallying to its 52-week high on 01/20/22, shares of the company touched a low of $1.55 and a high of $403.20 in 52 weeks. It has reached a new high 3 times so far this year and lost -99.25% or -$303.23 in price. In spite of this, the price is down -99.09% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

Baudax Bio Inc. (BXRX) has a trailing price-to-earnings (P/E) ratio of 0.51. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.00.

Financial Health

The quick ratio of Baudax Bio Inc. for the three months ended June 29 was 0.30, and the current ratio was 0.50, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at -$1.36 million compared to revenue of $1.08 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Baudax Bio Inc.’s return on assets was -56.20%.

Earnings Surprise

For the three-month period that ended June 29, Baudax Bio Inc. had $2.18 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$29.21 million in the quarter, while revenues of -$7.53 million were grew 41.94%. The analyst consensus anticipated Baudax Bio Inc.’s latest quarter earnings to come in at -$1.27 per share, but it turned out to be -$0.06, a 95.30% surprise. For the quarter, EBITDA amounted to -$28.01 million. Shareholders own equity worth $0.5 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Baudax Bio Inc. (BXRX) price momentum. RSI 9-day as of the close on 28 December was 57.33%, suggesting the stock is Neutral, with historical volatility in this time frame at 322.98%.

As of today, BXRX’s price is $2.64 +61.50% or $1.39 from its 5-day moving average. BXRX is currently trading -37.29% lower than its 20-day SMA and -87.99% lower than its 100-day SMA. However, the stock’s current price level is -55.27% below the SMA50 and -94.37% below the SMA200.

The stochastic %K and %D were 23.06% and 17.10%, respectively, and the average true range (ATR) was 0.94. With the 14-day stochastic at 41.75% and the average true range at 0.95, the RSI (14) stands at 49.27%. The stock has reached 0.35 on the 9-day MACD Oscillator while the 14-day reading was at -0.04.

Analyst Ratings

JMP Securities launched coverage on Baudax Bio Inc. (NASDAQ: BXRX) in its analyst report released on May 15, 2020. The firm assigned the stock a Mkt outperform rating.

What is BXRX’s price target for the next 12 months?

Analysts predict a range of price targets between $24.00 and $24.00, with a median target of $24.00. Taking a look at these predictions, the average price target given by analysts for Baudax Bio Inc. (BXRX) stock is $24.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here